Oral Drug Eased Hereditary Angioedema Attacks
A new oral capsule outperformed placebo in a recent clinical trial for patients with hereditary angioedema.
Updated on Oct. 10, 2026 in Allergies
Live Poll
Do you believe new oral treatments will improve quality of life for people with chronic conditions?
The investigational drug deucrictibant provided faster symptom relief for hereditary angioedema (HAE) attacks compared to placebo in the phase 3 RAPIDe-3 trial. The results suggest a potential new oral on-demand treatment option for patients currently relying on injectable therapies.
Why it matters
Most current on-demand HAE therapies require parenteral administration, which can be cumbersome for patients to manage during an acute attack. This oral alternative could significantly improve treatment accessibility and convenience for those living with the condition.
In a phase 3 randomized crossover trial involving 134 participants, a 20-mg oral capsule of deucrictibant achieved symptom relief in 83 percent of attacks within 4 hours. Researchers noted the trial results remain preliminary until long-term data collection is complete.
The players
Pharvaris
A pharmaceutical company focused on developing therapies for bradykinin-mediated diseases like hereditary angioedema.
FDA
The U.S. regulatory agency responsible for evaluating the safety and efficacy of new drug applications.
The details
Deucrictibant functions by directly blocking the bradykinin B2 receptor, which prevents the signaling pathway that leads to the swelling and pain characteristic of HAE attacks. By neutralizing this receptor at the source, the drug stops the progression of symptoms more rapidly than current standards. Participants in the study self-administered the treatment for two qualifying attacks, allowing for a direct comparison against placebo in a real-world setting.
Timeline
October 8, 2026: Trial results were published in The Lancet.
April 23, 2027: The FDA is expected to reach a decision on the drug application.
Health Landscape
The RAPIDe-3 clinical trial represents a significant shift toward oral, on-demand management for hereditary angioedema. This development marks a potential departure from the current reliance on injectable therapies for acute symptom control.
If you or a family member manage HAE, this research suggests that future oral options may eventually provide a more portable and convenient way to address symptom onset. Speak with your doctor about your current treatment plan and whether any new options under regulatory review may be relevant to your care.
The takeaway
Deucrictibant offers a promising oral alternative to traditional injectable HAE rescue medications by directly targeting bradykinin receptors. Patients should continue working closely with their physicians to monitor for updates as clinical trials move toward potential regulatory approval.
What happens next
The FDA is scheduled to announce a regulatory decision regarding the deucrictibant new drug application on April 23, 2027.
Further reading
For more information on managing the condition, visit our Allergies section.
More information
Review the full RAPIDe-3 clinical trial study results01296-1/fulltext) published in The Lancet.
Source note: This article includes information reported by Hcplive.
Live Poll
Do you believe new oral treatments will improve quality of life for people with chronic conditions?
